Physician profile
Libbie S Lapp
NPI 1225104052
$2,145.19
in general payments reported to CMS, 2019-2025
13 companies · $54.98 in 2025
The $54.98 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $564 · 2023: $802 · 2024: $349 · 2025: $54.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.95 | 2021-2024 | |
| Lilly USA, LLC | $304.34 | 2021-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $288.96 | 2021-2025 | |
| Amgen INC. | $148.53 | 2021-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $129.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $119.48 | 2022-2023 | Sotyktu |
| Incyte Corporation | $74.47 | 2022-2023 | Opzelura |
| Janssen Biotech, INC. | $62.24 | 2022-2023 | Tremfya |
| Ucb, INC. | $61.82 | 2022-2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $44.15 | 2021-2022 | |
| Pfizer INC. | $41.83 | 2021-2022 | |
| Integra Lifesciences Corporation | $35.95 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Genzyme Corporation | $17.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libbie Lapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.